Thermoresponsive polymeric radionuclide delivery system--an injectable brachytherapy
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21324355
DOI
10.1016/j.ejps.2011.02.002
PII: S0928-0987(11)00035-2
Knihovny.cz E-resources
- MeSH
- Acrylamides chemical synthesis chemistry MeSH
- Acrylic Resins MeSH
- Brachytherapy methods MeSH
- Radiation Dosage MeSH
- Injections, Intralesional MeSH
- Humans MeSH
- Mice, Nude MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms pathology radiotherapy MeSH
- Drug Carriers chemical synthesis chemistry MeSH
- Polymers chemical synthesis chemistry MeSH
- Radiopharmaceuticals administration & dosage chemical synthesis chemistry therapeutic use MeSH
- Iodine Radioisotopes administration & dosage chemistry therapeutic use MeSH
- Solubility MeSH
- Temperature * MeSH
- Dose-Response Relationship, Radiation MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acrylamides MeSH
- Acrylic Resins MeSH
- Drug Carriers MeSH
- poly-N-isopropylacrylamide MeSH Browser
- Polymers MeSH
- Radiopharmaceuticals MeSH
- Iodine Radioisotopes MeSH
Brachytherapy is of increasing popularity in clinical oncology for the local therapy of solid tumors due to high radiation doses delivered to malignant tissue while keeping the whole-body radiation burden low. Pronounced dose-dependent tumor growth reduction was achieved by single dose of injectable intratumoral brachytherapy with iodine-131-labeled thermoresponsive polymer [poly(N-isopropyl acrylamide)] in murine xenograft model (PC3 human prostate adenocarcinoma). The two doses of radionuclide were used, 2 MBq/mouse and 25 MBq/mouse. The higher dose caused gradual tumor volume reduction and 2 of 6 mice from this group were cured. The lower dose caused tumor growth retardation only. In both cases there were no signs of inflammation. The effects of both doses were statistically significant compared to untreated controls. Such injectable system should keep advantages of brachytherapy while making system administration easier and less invasive (injection instead of implantation), patient-tailored (splitting of doses into several depoes) and bioerodable.
References provided by Crossref.org
